92 related articles for article (PubMed ID: 27725387)
1. [Investigation into the Establishment of Indicators for Pharmaceutical Intervention in Cancer Pharmacotherapy].
Kimura M
Yakugaku Zasshi; 2016; 136(10):1379-1384. PubMed ID: 27725387
[TBL] [Abstract][Full Text] [Related]
2. [Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer].
Kimura M; Morihata K; Ito D; Iwai M; Okada K; Usami E; Nakao T; Yoshimura T; Yasuda T
Gan To Kagaku Ryoho; 2010 May; 37(5):829-34. PubMed ID: 20495311
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer.
Kimura M; Usami E; Yoshimura T; Yasuda T; Kaneoka Y; Teramachi H; Sugiyama T; Tsuchiya T
J Pharm Pract; 2013 Aug; 26(4):409-14. PubMed ID: 23353075
[TBL] [Abstract][Full Text] [Related]
4. [Tegafur/gimeracil/oteracil (Teysuno), by oral administration].
Duh D; Warnez M
J Pharm Belg; 2013 Dec; (4):35-6. PubMed ID: 24449972
[No Abstract] [Full Text] [Related]
5. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
[TBL] [Abstract][Full Text] [Related]
7. [TS-1 therapy for advanced gastric cancer].
Kurihara M; Koizumi W; Hasegawa K; Sakata Y; Ohtsu A; Taguchi T
Nihon Rinsho; 2001 Apr; 59 Suppl 4():393-7. PubMed ID: 11424413
[No Abstract] [Full Text] [Related]
8. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
[TBL] [Abstract][Full Text] [Related]
9. [The Importance of Medication History Management by Hospital and Community Pharmacists for Oral Anticancer Drug S-1(Tegafur/Gimeracil/Oteracil Potassium)--A Retrospective Study].
Maeda M; Saito Y; Makino Y; Iwase H; Hayashi Y
Gan To Kagaku Ryoho; 2016 Jan; 43(1):79-83. PubMed ID: 26809530
[TBL] [Abstract][Full Text] [Related]
10. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
11. [Determining S-1 dosage at hospitals prioritizing cancer chemotherapy].
Morimoto S; Kitada N; Anami S; Miyabe T; Morita S; Watari M; Yamasaki H; Imamura H; Furukawa H; Hasegawa K; Tabuse K
Gan To Kagaku Ryoho; 2008 Apr; 35(4):615-8. PubMed ID: 18449980
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of outpatient clinical pathway, including the supportive therapy of S-1+cisplatin combination therapy for gastric cancer].
Fujii C; Imamura H; Kawase T; Kawabata R; Fujino M; Sumida R; Iseki C; Hachino Y; Furukawa H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2316-8. PubMed ID: 23268062
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer: a single-center retrospective study.
Ishizuna K; Ninomiya J; Ogawa T; Kojima M; Tsuji E; Kawashima M; Nozaki M; Yamagishi H; Ueda Y
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2577-82. PubMed ID: 25596051
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.
Takahari D; Hamaguchi T; Yoshimura K; Katai H; Ito S; Fuse N; Kinoshita T; Yasui H; Terashima M; Goto M; Tanigawa N; Shirao K; Sano T; Sasako M
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1423-8. PubMed ID: 20809123
[TBL] [Abstract][Full Text] [Related]
15. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
[TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Akasaka O; Iwase S; Miwa H; Ando T; Morita S; Koh R; Kasama M; Matsueda R; Anan H
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1833-7. PubMed ID: 19920384
[TBL] [Abstract][Full Text] [Related]
17. [Postoperative chemotherapy with a novel oral anticancer drug composed of tegafur, gimeracil and oteracil potassium to curability C scirrhus type gastric cancer].
Iwatani Y; Shimada Y; Ohshima T; Kusunoki N; Yamazaki T; Miyazaki N
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1129-32. PubMed ID: 11525030
[TBL] [Abstract][Full Text] [Related]
18. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
19. Eccrine squamous syringometaplasia of underlying syringoma associated with Tegafur/Gimeracil/Oteracil (TS-1).
Kim J; Kim SH; Lee MG; Chung KY; Kim DS
Acta Derm Venereol; 2015 Nov; 95(8):999-1000. PubMed ID: 25766447
[No Abstract] [Full Text] [Related]
20. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
